Moleculin Biotech, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Moleculin Biotech, Inc. (MBRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 161.86 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-18
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-12-31 was -1.39M shares.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-09-30 was 10.00K shares.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 161.86K shares, a 70.17% decline from fiscal 2024.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 542.67K shares, a 435.17% increase from fiscal 2023.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 101.40K shares, a 87.97% decline from fiscal 2022.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 842.83K shares, a 57.58% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | 161.86K shares 10-K · filed 2026-03-18 | |||||
| 2024-12-31 | 542.67K shares 10-K · filed 2025-03-21 | |||||
| 2023-12-31 | -1.39M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | -1.39M shares derived: sum of 2 quarters · filed 2024-03-22 | 101.40K shares 10-K · filed 2024-03-22 | |||
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 1.50M shares 10-Q · filed 2023-11-13 | ||||
| 2023-06-30 | 1.50M shares 10-Q · filed 2023-08-10 | |||||
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | 10.00K shares derived: sum of 2 quarters · filed 2023-03-22 | 821.16K shares derived: sum of 3 quarters · filed 2023-03-22 | 842.83K shares 10-K · filed 2023-03-22 | ||
| 2022-09-30 | 10.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 821.16K shares derived: sum of 2 quarters · filed 2022-11-10 | 842.83K shares 10-Q · filed 2022-11-10 | 844.83K shares derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2022-06-30 | 811.16K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | 832.83K shares 10-Q · filed 2022-08-12 | 834.83K shares derived: sum of 3 quarters · filed 2022-08-12 | 834.83K shares derived: sum of 4 quarters · filed 2022-08-12 | ||
| 2022-03-31 | 21.67K shares 10-Q · filed 2022-05-11 | 23.67K shares derived: sum of 2 quarters · filed 2022-05-11 | 23.67K shares derived: sum of 3 quarters · filed 2022-05-11 | |||
| 2021-12-31 | 2.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | 2.00K shares derived: sum of 2 quarters · filed 2022-03-24 | 534.87K shares 10-K · filed 2022-03-24 | |||
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 532.87K shares 10-Q · filed 2021-11-10 | ||||
| 2021-06-30 | 532.87K shares 10-Q · filed 2021-08-11 | |||||
| 2020-12-31 | -1.29M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | 177.47K shares derived: sum of 2 quarters · filed 2021-03-24 | 267.47K shares 10-K · filed 2021-03-24 | |||
| 2020-09-30 | 1.46M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | 1.55M shares 10-Q · filed 2020-11-12 | ||||
| 2020-07-31 | 224.96K shares 10-K · filed 2021-03-24 | 1.35M shares 10-Q · filed 2020-11-12 | ||||
| 2020-06-30 | 90.00K shares 10-Q · filed 2020-08-12 | |||||
| 2019-12-31 | 55.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | 1.13M shares derived: sum of 2 quarters · filed 2020-03-19 | 1.17M shares derived: sum of 3 quarters · filed 2020-03-19 | 1.17M shares 10-K · filed 2020-03-19 | ||
| 2019-09-30 | 1.07M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | 1.11M shares derived: sum of 2 quarters · filed 2019-11-12 | 1.11M shares 10-Q · filed 2019-11-12 | 1.17M shares derived: sum of 4 quarters · filed 2019-11-12 | ||
| 2019-06-30 | 45.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-16 | 45.00K shares 10-Q · filed 2019-08-16 | 95.00K shares derived: sum of 3 quarters · filed 2019-08-16 | 115.00K shares derived: sum of 4 quarters · filed 2019-08-16 | ||
| 2019-03-31 | 0.00 shares 10-Q · filed 2019-05-13 | 50.00K shares derived: sum of 2 quarters · filed 2019-05-13 | 70.00K shares derived: sum of 3 quarters · filed 2019-05-13 | 1.25M shares derived: sum of 4 quarters · filed 2019-05-13 | ||
| 2018-12-31 | 50.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | 70.00K shares derived: sum of 2 quarters · filed 2019-02-21 | 1.25M shares derived: sum of 3 quarters · filed 2019-02-21 | 1.48M shares 10-K · filed 2019-02-21 | ||
| 2018-09-30 | 20.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | 1.20M shares derived: sum of 2 quarters · filed 2018-11-13 | 1.43M shares 10-Q · filed 2018-11-13 | 2.10M shares derived: sum of 4 quarters · filed 2018-11-13 | ||
| 2018-06-30 | 1.18M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | 1.41M shares 10-Q · filed 2018-08-10 | 2.08M shares derived: sum of 3 quarters · filed 2018-08-10 | 2.22M shares derived: sum of 4 quarters · filed 2018-08-10 | ||
| 2018-03-31 | 230.00K shares 10-Q · filed 2018-05-14 | 905.00K shares derived: sum of 2 quarters · filed 2018-05-14 | 1.04M shares derived: sum of 3 quarters · filed 2018-05-14 | 1.04M shares derived: sum of 4 quarters · filed 2018-05-14 | ||
| 2017-12-31 | 675.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-28 | 815.00K shares derived: sum of 2 quarters · filed 2018-03-28 | 815.00K shares derived: sum of 3 quarters · filed 2018-03-28 | 835.00K shares 10-K · filed 2018-03-28 | ||
| 2017-09-30 | 140.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | 140.00K shares derived: sum of 2 quarters · filed 2017-11-13 | 160.00K shares 10-Q · filed 2017-11-13 | 160.00K shares derived: sum of 4 quarters · filed 2018-03-28 | ||
| 2017-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | 20.00K shares 10-Q · filed 2017-08-11 | 20.00K shares derived: sum of 3 quarters · filed 2018-03-28 | |||
| 2017-03-31 | 20.00K shares 10-Q · filed 2017-05-12 | 20.00K shares derived: sum of 2 quarters · filed 2018-03-28 | ||||
| 2016-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-28 | 460.00K shares 10-K · filed 2018-03-28 | ||||
| 2016-09-30 | 460.00K shares 10-Q · filed 2016-11-21 | |||||
| 2015-12-31 | 200.00K shares 10-K · filed 2017-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |